6YC Stock Chart & Stats
€0.30
>-€0.01(-0.34%)
At close: 4:00 PM EDT
€0.30
>-€0.01(-0.34%)
Day’s Range― - ―
52-Week Range€0.27 - €0.68
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€46.33M
Enterprise Value€665.00
Total Cash (Recent Filing)€37.11M
Total Debt (Recent Filing)€21.37M
Price to Earnings (P/E)―
Beta1.03
Next Earnings
Oct 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.71
Shares Outstanding157,215,040
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio1.41
Price to Book (P/B)2.61
Price to Sales (P/S)7.63
P/FCF Ratio-7.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)€13.84M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables Revenue ModelThe installed monitoring base can support recurring consumables revenue whenever systems are used in clinical workflows. This model links future sales to hospital adoption, procedure volumes, and utilization, potentially improving revenue visibility and customer retention as deployments expand.
Commercialization Progress And Improving Gross MarginRapid multi-year revenue expansion indicates meaningful commercialization progress, while higher gross margin suggests improving product economics. If maintained, this combination can provide greater operating leverage as sales scale and help narrow the gap between revenue growth and eventual profitability.
Low Financial LeverageLow leverage reduces near-term solvency pressure and limits the interest burden on a company that is still loss-making. The relatively flexible balance sheet gives Senzime more capacity to support operations and pursue growth without the constraints associated with heavy debt obligations.
Bears Say
Severe Ongoing UnprofitabilityDeep losses show that the current revenue base is not yet sufficient to cover the operating cost structure. Persistent negative profitability can delay self-funded growth, weaken returns on invested capital, and increase the likelihood that future expansion depends on external financing.
Persistent Cash Burn And Funding NeedsSustained operating and free cash outflows indicate that Senzime is consuming cash rather than funding its activities internally. Continued burn can reduce financial flexibility over the next several quarters and create recurring funding needs, even though current leverage remains low.
Recent Revenue Momentum Has StalledA sharp deterioration in recent revenue growth raises concern that earlier commercialization momentum is not currently translating into continued expansion. Slower sales can postpone operating leverage, make fixed costs harder to absorb, and extend the period before the business reaches sustainable profitability.
Senzime AB News
6YC FAQ
What was Senzime AB’s price range in the past 12 months?
Senzime AB lowest stock price was €0.27 and its highest was €0.68 in the past 12 months.
What is Senzime AB’s market cap?
Senzime AB’s market cap is €46.33M.
When is Senzime AB’s upcoming earnings report date?
Senzime AB’s upcoming earnings report date is Oct 29, 2026 which is in 51 days.
How were Senzime AB’s earnings last quarter?
Senzime AB released its earnings results on Jul 16, 2026. The company reported -€0.012 earnings per share for the quarter.
Is Senzime AB overvalued?
According to Wall Street analysts Senzime AB’s price is currently Overvalued.
Does Senzime AB pay dividends?
Senzime AB does not currently pay dividends.
What is Senzime AB’s EPS estimate?
Senzime AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Senzime AB have?
Senzime AB has 157,215,040 shares outstanding.
What happened to Senzime AB’s price movement after its last earnings report?
Senzime AB reported an EPS of -€0.012 in its last earnings report. Following the earnings report the stock price went down -8.14%.
Which hedge fund is a major shareholder of Senzime AB?
Currently, no hedge funds are holding shares in DE:6YC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Senzime AB
Senzime AB (publ) is a medical technology firm specializing in the creation and distribution of advanced patient monitoring solutions. These systems are designed to oversee patients undergoing anesthesia across various global markets, including Europe, Oceania, Asia, Canada, and the United States. Among its primary offerings is the TetraGraph, a sophisticated monitor designed to assess and display muscle function in surgical patients administered neuromuscular blocking agents, by stimulating, measuring, and analyzing responses. This system is complemented by the TetraSens electrode array, featuring two proximal stimulating electrodes for precise recording and reference. For data management, TetraConnect serves as a portal, allowing clinicians to conveniently access, view, and export TetraGraph data records in PDF or Excel formats. Furthermore, TetraGraph Device Connectivity facilitates the transfer of data from the TetraGraph Monitor to other patient monitoring systems, while the TetraGraph Philips Interface specifically enables the transmission of critical neuromuscular monitoring parameters—such as TOFC, TOFR, PTC, and TOF bars—to Philips patient monitors, with readings visible on the Philips Intellivue Monitor. Senzime is also actively developing the CliniSenz Analyzer, intended for continuous postoperative patient monitoring within hospital settings. Another innovation in its pipeline is the Onzurf Probe, a sterile, CE-marked single-use device leveraging micro-dialysis technology for continuous sampling from gastrointestinal organs, including the esophagus, stomach, and liver. The company maintains a strategic licensing and connectivity partnership with Masimo. This collaboration focuses on developing and commercializing the TetraGraph Smart Cable Module, designed to integrate seamlessly with Masimo's Root monitoring system and their digital hubs, thereby enabling interaction with hospital clinical information systems and electronic health records. Established in 1999, Senzime AB (publ) operates from its headquarters in Uppsala, Sweden.
Technical Analysis
Paxman AB
―
SciBase Holding AB
―
Bactiguard Holding AB
―
Acarix AB
―
Sedana Medical AB
―